Prosecution Insights
Last updated: November 04, 2026
Application No. 18/417,251

DNA BARCODE FOR SCREENING TOTAL SOLUBLE AMINO ACID CONTENT INDEX OF FLOCCULARIA LUTEOVIRENS

Final Rejection §112
Filed
Jan 19, 2024
Priority
Nov 19, 2021 — CN 202111399046.1 +1 more
Examiner
CHUNDURU, SURYAPRABHA
Art Unit
1681
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Xizang Vocational Technical College
OA Round
2 (Final)
53%
Grant Probability
Moderate
3-4
OA Rounds
1y 1m
Est. Remaining
71%
With Interview

Examiner Intelligence

Grants 53% of resolved cases
53%
Career Allowance Rate
391 granted / 734 resolved
-6.7% vs TC avg
Strong +17% interview lift
Without
With
+17.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
49 currently pending
Career history
797
Total Applications
across all art units

Statute-Specific Performance

§101
4.5%
-35.5% vs TC avg
§103
31.4%
-8.6% vs TC avg
§102
29.7%
-10.3% vs TC avg
§112
18.7%
-21.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 734 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION 1.The Applicant’s response to the office action filed on August 13, 2026 is acknowledged. Status of the Application 2. Claims 4-8 are pending under examination. Claims 1-3, and 9-11 are withdrawn from further consideration as being drawn to nonelected group. The Applicant’s arguments have been fully considered and found persuasive for the following reasons. Response to Arguments: 3. The objection to the sequence identifiers in the specification has been withdrawn in view of the amendment. 4. The rejection of claims under 35 USC 112(b) has been withdrawn in view of the amendment. 5. The rejection of claims under obviousness type of double patenting has been withdrawn in view of the terminal disclaimer. New Rejections necessitated by the Amendment Claim Rejections - 35 USC § 112 6. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. A. Claims 4-8 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 4 recites ‘to perform’ in step S2. It is not clear if the method requires performing fluorescent polymerase chain reaction with the extracted genomic DNA or does it indicate latent characteristic. Further, step S2 requires one or more primer pairs to obtain amplification products, wherein the primer pairs are used for amplifying DNA barcodes and allowable barcode combinations are defined as….,. It is not clear if the method requires amplifying the genomic DNA with at least one primer pair or all primer pairs to produce the amplification products. B. Claims 4-8 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 4, step S3 recites the limitation "the fragment length and fixed copy number of simple sequence repeat repetitive elements" in line 4-6 of step S3. There is insufficient antecedent basis for this limitation in the claim because the fragment length and fixed tandem copy number lacks support for a fragment length and fixed tandem copy number of SSR repetitive elements in the preceding lines of the method steps and it is not clear what the limitation is referring to. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SURYAPRABHA CHUNDURU whose telephone number is (571)272-0783. The examiner can normally be reached 8.00am-4.30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gary Benzion can be reached at 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Suryaprabha Chunduru Primary Examiner Art Unit 1681 /SURYAPRABHA CHUNDURU/Primary Examiner, Art Unit 1681
Read full office action

Prosecution Timeline

Jan 19, 2024
Application Filed
Jun 16, 2026
Non-Final Rejection mailed — §112
Aug 13, 2026
Response Filed
Oct 19, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767974
Methods for the Analysis of Circulating Microparticles
5y 10m to grant Granted Oct 20, 2026
Patent 12767975
Multiplex Preparation of Barcoded Gene Specific DNA Fragments
4y 2m to grant Granted Oct 20, 2026
Patent 12767977
METHODS AND KITS FOR THE DETECTION OF SARS-COV-2
4y 0m to grant Granted Oct 20, 2026
Patent 12735738
CIRCULAR PROBES AND METHODS FOR SAMPLE ANALYSIS
3y 9m to grant Granted Sep 15, 2026
Patent 12708886
METHOD OF GENERATING MONODISPERSE EMULSIONS
6y 5m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
53%
Grant Probability
71%
With Interview (+17.4%)
3y 10m (~1y 1m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 734 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month